 |

Home » About Us » About Us
About Us
We are a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists and other physicians. Key elements of our business strategy include:
- Increasing sales of our ZEGERID® and GLUMETZA® brand prescription products
- ZEGERID (omeprazole/sodium bicarbonate) Capsules and Powder for Oral Suspension for the treatment of certain upper gastrointestinal diseases and disorders (for full prescribing and safety information visit www.zegerid.com), and
- GLUMETZA (metformin hydrochloride extended release tablets), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (for full prescribing and safety information visit www.glumetzaxr.com).
- Advancing the development of budesonide MMX® and rifamycin SV MMX®, our two lower gastrointestinal product candidates
- Budesonide MMX is being investigated in two multicenter Phase III clinical trials for the induction of remission of mild or moderate ulcerative colitis.
- Rifamycin SV MMX has been investigated in a Phase II clinical program in travelers' diarrhea.
- Maximizing the value of our proprietary proton pump inhibitor (PPI) technology through strategic alliances
- Expanding our product portfolio to further leverage our commercial capabilities
Our goal is to become a premier specialty biopharmaceutical company with a diversified portfolio of commercial and development products. Our stock trades on the NASDAQ Global Market under the symbol "SNTS".
|

|